[Urinary lysozyme, beta-2-microglobulin, and alpha-glucosidase during cisplatin therapy].
M
M
Airoldi
F
F
Pecchio
F
F
Albanese
V
V
Mastromatteo
A
A
Gariboldi
G
G
Di Costanzo
M
M
Fazio
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001623:Betamethasone / Q000008:administration & dosage; D015415:Biomarkers; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D004231:Diuresis / Q000187:drug effects; D005440:Fluid Therapy; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control / Q000652:urine; D007677:Kidney Function Tests; D007684:Kidney Tubules / Q000187:drug effects*; D008727:Methotrexate / Q000008:administration & dosage; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000652:urine; D009113:Muramidase / Q000652:urine*; D009363:Neoplasm Proteins / Q000652:urine; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D014750:Vincristine / Q000008:administration & dosage; D000520:alpha-Glucosidases / Q000652:urine*; D001613:beta 2-Microglobulin / Q000652:urine*
D015415:Biomarkers; D009363:Neoplasm Proteins; D001613:beta 2-Microglobulin; D001761:Bleomycin; D014750:Vincristine; D001623:Betamethasone; D009113:Muramidase; D000520:alpha-Glucosidases; D002945:Cisplatin; D008727:Methotrexate